Physician profile
Audra Doyle
NPI 1417347451
$838.28
in general payments reported to CMS, 2019-2025
16 companies · $21.36 in 2025
The $21.36 reported for 2025 was less than what a typical Adult Health (Nurse Practitioner) provider received nationally (typical 2025 total: $182).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $803 · 2024: $13.89 · 2025: $21.36.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $35.25.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $35.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $229.97 | 2021 | |
| Abbvie INC. | $170.87 | 2021-2024 | |
| Eisai INC. | $62.69 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $62.31 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $60.03 | 2021 | |
| Lilly USA, LLC | $44.77 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $39.91 | 2021 | |
| Amarin Pharma, INC. | $29.30 | 2021 | |
| Sanofi-Aventis U.S. LLC | $25.54 | 2021 | |
| Pharmacosmos Therapeutics INC. | $21.36 | 2025 | Monoferric |
| Genentech USA, INC. | $19.95 | 2021 | |
| Upsher-Smith Laboratories LLC | $16.03 | 2021 | |
| Dexcom, INC. | $15.61 | 2021 | |
| Janssen Pharmaceuticals, INC | $13.56 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $13.28 | 2021 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $13.10 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Audra Doyle listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.